Novo shares hit after FDA review highlights Tresiba heart risks

Shares of Novo Nordisk ($NVO) took a hit this morning after the FDA released a review of its long-acting insulin Tresiba (degludec) highlighting a warning that the drug presents a greater risk to the heart than other diabetes medications. That raises the prospect that an outside panel of experts could demand more safety studies when it meets to review Novo's application on Thursday. Novo needs tresiba, a potential blockbuster, to counter growing competition from Sanofi's ($SNY) Lantus, which earned close to $5 billion last year. Just weeks ago an EU panel gave Tresiba a thumbs-up. Story

 

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.